Τίτλος:
The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
What is known and objective: In the outpatient setting, sodium-glucose co-transporter 2 inhibitors (SGLT2i) are recognized as effective agents to optimize glycaemia and also developing robust evidence for cardiovascular (CV) and renal protection in people with type 2 diabetes, particularly those at higher risk. However, data on the safety and efficacy of these drugs in hospitalized patients remain limited. The purpose of this review is to discuss the balance between risks and benefits of SGLT2i use in the inpatient setting. Methods: PubMed, Embase and Google Scholar databases were searched to identify relevant published work. Available evidence on the mechanisms of action and the safety profile of SGLT2i in the context of their use in hospitalized individuals are summarized and discussed in this narrative review. Results and discussion: The rationale behind the use of these agents in the inpatient setting is based on the low risk of hypoglycaemia, the practical dosing scheme and the potential to decrease subsequent heart failure admission rates. In addition, data from animal studies indicate the ability of SGLT2i to ameliorate oxidative stress, suppress sympathetic activity, enhance autophagy and promote cardiac remodelling, when administered in the acute phase of CV episodes. On the other hand, these drugs have been linked to specific adverse events related to their mechanism of action, including an increased risk of euglycaemic diabetic ketoacidosis and volume depletion, which raises concerns over their usefulness in inpatients, particularly individuals with multimorbidities. What is new and conclusion: Potential benefits deriving from the use of SGLT2i in the inpatient setting cannot mitigate possible risks, at least until robust evidence on their efficacy in hospitalized individuals become available. The concept of administering these agents in the acute phase of CV episodes, in people with or without diabetes, requires further evaluation in appropriately designed clinical studies. © 2020 John Wiley & Sons Ltd
Συγγραφείς:
Koufakis, T.
Mustafa, O.G.
Ajjan, R.A.
Garcia-Moll, X.
Zebekakis, P.
Dimitriadis, G.
Kotsa, K.
Περιοδικό:
Journal of Clinical Pharmacy and Therapeutics
Εκδότης:
Wiley-Blackwell Publishing Ltd
Λέξεις-κλειδιά:
canagliflozin; dapagliflozin; empagliflozin; placebo; sodium glucose cotransporter 2 inhibitor; antidiabetic agent, antidiabetic activity; antioxidant activity; autophagy (cellular); cardiovascular disease; data base; diabetic ketoacidosis; disease course; drug safety; heart failure; heart protection; heart ventricle remodeling; hospital admission; hospital patient; human; hypoglycemia; mycosis; non insulin dependent diabetes mellitus; nonhuman; oxidative stress; randomized controlled trial (topic); renal protection; Review; risk benefit analysis; surgical patient; sympathetic tone; administration and dosage; adverse event; animal; cardiovascular disease; diabetic ketoacidosis; drug effect; glucose blood level; hospital patient, Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Humans; Hypoglycemic Agents; Inpatients; Sodium-Glucose Transporter 2 Inhibitors
